SCHEMBL2905922

SCHEMBL2905922

COc1ccc(-c2ccc(-n3cc(CN4CCNCC4)c(-c4ccco4)n3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
KDM4E B2RXH2 7/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.48
MAPT P10636 3/20 0.45
NPC1 O15118 2/20 0.45
HTT P42858 2/20 0.45
SSTR5 P35346 3/20 0.44
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ACVRL1 P37023 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908994 0.89 ALDH1A1 (0.52) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2904839 0.87 NPSR1 (0.52) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2902226 0.85 SSTR5 (0.49) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2909630 0.85 ALDH1A1 (0.62) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2901673 0.83 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2903064 0.83 ALDH1A1 (0.52) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2904795 0.82 ALDH1A1 (0.52) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL2908986 0.82 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAMAPT
Morpholine SCHEMBL2905728 0.79 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL5230456 0.79 SMO (0.46) ALDH1A1KDM4ELMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885KDM4E 3489/4885LMNA 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.